Perspective Therapeutics (CATX) Research & Development (2010 - 2026)
Perspective Therapeutics (CATX) reported Research & Development of $21.4 million for Q1 2026, up 49.12% on a YoY basis from $14.3 million in Q1 2025, and up 49.12% sequentially from $14.3 million in Q1 2025.
Perspective Therapeutics (CATX) Research & Development (2010 - 2026) Analysis & Trends
Perspective Therapeutics (CATX) has 17 years of Research & Development data on file, last reported at $21.4 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development rose 49.12% year-over-year to $21.4 million; the trailing twelve-month figure through Mar 2026 stood at $60.6 million (up 24.93% YoY), and the FY2025 full-year result was $84.2 million, up 102.26% from the prior year.
- Research & Development advanced to $21.4 million in Q1 2026, from $14.3 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $21.4 million in Q1 2026 to a low of $468000.0 in Q4 2022.
- A 5-year average of $7.4 million and a median of $6.3 million in 2023 frame the typical range for Research & Development.
- Across the five-year window, Research & Development slumped 33.33% in 2022 and jumped 1412.82% in 2023, its largest moves.
- Tracing CATX's Research & Development over 5 years: stood at $468000.0 in 2022, then jumped by 1412.82% to $7.1 million in 2023, then surged by 81.96% to $12.9 million in 2024, then increased by 11.25% to $14.3 million in 2025, then soared by 49.12% to $21.4 million in 2026.
- Business Quant data shows CATX's Research & Development at $21.4 million in Q1 2026, $14.3 million in Q1 2025, and $12.9 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 767.00 Mn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 413.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 671.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 516.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 263.30 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 145.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -461.27 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 345.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Perspective Therapeutics | 146.05 Mn | 146.05 Mn | - | 21.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.37 Mn |
| Mar 31, 2025 | 14.33 Mn |
| Dec 31, 2024 | 12.88 Mn |
| Sep 30, 2024 | 12.03 Mn |
| Jun 30, 2024 | 9.28 Mn |
| Mar 31, 2024 | 7.45 Mn |
| Dec 31, 2023 | 7.08 Mn |
| Sep 30, 2023 | 5.55 Mn |
| Jun 30, 2023 | 5.37 Mn |
| Mar 31, 2023 | 3.31 Mn |
| Dec 31, 2022 | 468,000.00 |
| Sep 30, 2022 | 2.05 Mn |
| Jun 30, 2022 | 1.35 Mn |
| Mar 31, 2022 | 549,000.00 |
| Dec 31, 2021 | 702,000.00 |
| Sep 30, 2021 | 761,000.00 |
| Mar 31, 2021 | 581,000.00 |
| Dec 31, 2020 | 285,000.00 |
| Sep 30, 2020 | 312,000.00 |
| Jun 30, 2020 | 2.17 Mn |